Guideline for the prevention and control of occupational exposure risks to cytotoxic drugs in medical institutions

ZOU Linke; YAN Junfeng; LIU Hui; LYU Ziyan

doi:10.6039/j.issn.1001-0408.2023.13.01

您当前的位置：

首页 >

文章列表页 >

Guideline for the prevention and control of occupational exposure risks to cytotoxic drugs in medical institutions

更新时间：2023-08-15

- Guideline for the prevention and control of occupational exposure risks to cytotoxic drugs in medical institutions
- ZHONGGUO YAOFANG Vol. 34, Issue 13, Pages: 1537-1546(2023)
- 作者机构：
  
  1.四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部个体化药物治疗四川省重点实验室，成都　610072
  2.电子科技大学医学院，成都　610072
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.13.01
  CLC： R95
- Published：15 July 2023，
  
  Received：19 May 2023，
  
  Revised：19 June 2023，
扫描看全文
邹林珂,闫峻峰,刘慧等.医疗机构细胞毒性药物职业暴露风险防控指南 ^Δ[J].中国药房,2023,34(13):1537-1546.

ZOU Linke,YAN Junfeng,LIU Hui,et al.Guideline for the prevention and control of occupational exposure risks to cytotoxic drugs in medical institutions[J].ZHONGGUO YAOFANG,2023,34(13):1537-1546.
邹林珂,闫峻峰,刘慧等.医疗机构细胞毒性药物职业暴露风险防控指南 ^Δ[J].中国药房,2023,34(13):1537-1546. DOI： 10.6039/j.issn.1001-0408.2023.13.01.

ZOU Linke,YAN Junfeng,LIU Hui,et al.Guideline for the prevention and control of occupational exposure risks to cytotoxic drugs in medical institutions[J].ZHONGGUO YAOFANG,2023,34(13):1537-1546. DOI： 10.6039/j.issn.1001-0408.2023.13.01.

摘要

为医疗机构提供细胞毒性药物职业暴露风险防控策略，提高医务人员的防护意识，降低医务人员发生潜在的职业暴露风险，制定《医疗机构细胞毒性药物职业暴露风险防控指南》。依据《世界卫生组织指南制定手册》方法，收集细胞毒性药物从配送到医院开始到其进入医院后在运输、接收、储存、脱包、调剂、成品使用、废物处理各个环节存在的暴露风险问题，采用德尔菲法构建临床问题，采用循证研究方法形成相关证据体后，按照推荐分级的评价、制定与评估（GRADE）方法进行质量评价，并再次通过专家共识法对推荐意见及证据级别达成共识。将工程控制、行政控制和个人防护设备3个不同等级管控相结合，通过分级管控的方式，最终确定了37个临床问题，共形成36条推荐意见，旨在为医疗机构制定细胞毒性药物分级防控措施提供参考与补充。

Abstract

To provide prevention and control strategies of occupational exposure risks to cytotoxic drug in medical institutions，improve the awareness of protection among medical staff，and reduce potential occupational exposure risks，the

Guidelines for the Prevention and Control of Occupational Exposure Risk to Cytotoxic Drugs in Medical Institutions

is developed. Based on the

World Health Organization Guidelines Development Manual

，the exposure risk issues of the cytotoxic drug collected from the time that it entered the hospital to the several stages after delivery to hospital，such as transportation，receipt，storage，unpacking，dispensing，use of finished products，and waste disposal. Delphi method is used to construct identification of clinical issues，and evidence-based research method is used to develop relevant evidence. Quality evaluation is conducted by using the recommended GRADE method. The consensus is reached on the recommendation opinions and evidence levels through expert consensus method. By combining engineering controls，administrative controls and personal protective equipment at different levels，a graded control approach is established. A total of 37 clinical issues are identified，resulting in 36 recommendations. This guideline provides reference and supplementation for the formulation of cytotoxic drug prevention and control measures in medical institutions.

关键词

细胞毒性药物职业暴露风险防控指南医疗机构

Keywords

occupational exposurerisk prevention and controlguidelinemedical institutions

references

Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace [EB/OL]. （2019-07-23）[2023-06-02]. http//www.hse.gov.uk/healthservices/safe-use-cytotoxic-drugs.htmhttp://www.hse.gov.uk/healthservices/safe-use-cytotoxic-drugs.htm.

HIJIYA N，HUDSON M M，LENSING S，et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia[J]. JAMA，2007，297（11）：1207-1215.

GURUSAMY K S，BEST L M，TANGUAY C，et al. Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff[J]. Cochrane Database Syst Rev，2018，3（3）：1465-1858.

ENSSLIN A S，STOLL Y，PETHRAN A，et al.Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs[J]. Occup Environ Med，1994，51（4）：229-233.

TOUZIN K，BUSSIERES J F，LANGLOIS E，et al. Evaluation of surface contamination in a hospital hematology：oncology pharmacy[J]. J Oncol Pharm Pract，2009，15（1）：53-61.

MASON H J，BLAIR S，SAMS C，et al.Exposure to antineoplastic drugs in two UK hospital pharmacy units[J]. Ann Occup Hyg，2005，49（7）：603-610.

HALL A L，DEMERS P A，ASTRAKIANAKIS G，et al. Estimating national-level exposure to antineoplastic agents in the workplace：CAREX Canada findings and future research needs[J]. Ann Work Expo Health，2017，61（6）：656-658.

SOTTANI C，PORRO B，COMELLI M，et al.An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers[J].J Chromatogr B Analyt Technol Biomed Life Sci，2010，878（27）：2593-2605.

TOUZIN K，BUSSIÈRES J F，LANGLOIS E，et al. Cyclophosphamide contamination observed on the external surfaces of drug vials and the efficacy of cleaning on vial contamination[J]. Ann Occup Hyg，2008，52（8）：765-771.

HEDMER M，GEORGIADI A，BREMBERG E R，et al.Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden[J]. Ann Occup Hyg，2005，49（7）：629-637.

HAO M I，WANG T，ZHU J Q，et al. Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic compounding by Ⅳ：dispensing robot vs. manual compounding in biological safety cabinet[J]. J Oncol Pharm Pract，2022，28（7）：1487-1498.

National Institute for Occupational Safety and Health. NIOSH alert：preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings[EB/OL].（2018-02-07） [2023-06-02]. https：//www.cdc.gov/niosh/docs/2004-165/https://www.cdc.gov/niosh/docs/2004-165/.

POWER L A，COYNE J W. ASHP guidelines on handling hazardous drugs[J]. Am J Health Syst Pharm，2018，75（24）：1996-2031.

GALLANT C，BUSSIERES J，PLANTE R.Guidede prévention：manipulation sécuritaire des médicaments dangereux [EB/OL]. （2008-06）[2023-06-02]. http：//asstsas.qc.ca/publication/guide-de-prevention-manipulation-securitaire-des-medicaments-dangereux-gp65http://asstsas.qc.ca/publication/guide-de-prevention-manipulation-securitaire-des-medicaments-dangereux-gp65.

DAVUS L，SHEREEN N G. ISOPP standards for the safe handling of cytotoxics[J].J Oncol Pharm Pract，2022，28（3-suppl）：S1-S126.

杨克虎.世界卫生组织指南制定手册[M].兰州：兰州大学出版社，2013：1-75.

WINKLER G C，BARLE E L，GALATI G，et al. Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics[J].Regul Toxicol Pharmacol，2014，70（1）：46-53.

李正翔，张玉，张伶俐，等. 医疗机构药品遴选指南[J].中国药房，2022，33（7）：769-776.

MEADE E. Avoiding accidental exposure to intravenous cytotoxic drugs[J]. Br J Nurs，2014，23（16）：S34，S36-S34，S39.

EXECUTIVE S. Control of substances hazardous to health （fifth edition）：the control of substances hazardous to health regulations 2002 （as amended）[EB/OL].[2023-06-02]. http：//www.cbcsd.org.cn/sjk/HSE/policies/international/20130711/download/l5.pdfhttp://www.cbcsd.org.cn/sjk/HSE/policies/international/20130711/download/l5.pdf.

CONNO T H，MACKENZIE B，DEBORD D，et al. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings[EB/OL].（2010-09-01）[2023-06-02]. http：//www.cdc.gov/niosh/docs/2010-167/http://www.cdc.gov/niosh/docs/2010-167/.

EASTY A C，COAKLEY N，CHENG R，et al. Safe han- dling of cytotoxics：guideline recommendations[J]. Curr Oncol，2015，22（1）：e27-e37.

EDGAR-HUGHES M，BOSS K，COULLS S，et al. Safe handling of cytotoxic drugs and related wastes：guidelines for South Australian health services 2012[EB/OL]. （2012-03）[2023-06-02]. https：//www.researchgate.net/publication/266733922https://www.researchgate.net/publication/266733922.

POWER L A . Safe handling of hazardous drugs：reviewing standards for worker protection[EB/OL]. （2017-03-01） [2023-06-02]. https：//www.specialtypharmacycontinuum.com/download/Safe_handling_spc0417_WM.pdfhttps://www.specialtypharmacycontinuum.com/download/Safe_handling_spc0417_WM.pdf.

BERNABEU-MARTÍNEZ M A，RAMOS MERINO M，SANTOS GAGO J M，et al. Guidelines for safe handling of hazardous drugs：a systematic review[J]. PLoS One，2018，13（5）：e0197172.

INTERNATIONAL Society of Oncology Pharmacy Practicioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics[J]. J Oncol Pharm Pract，2007，13（Suppl）：1-81.

National Institute for Occupaional Safety and Health. Medical surveillance for healthcare workers exposed to hazardous drugs[EB/OL].[2023-06-02]. https：//stacks.cdc.gov/view/cdc/12110https://stacks.cdc.gov/view/cdc/12110.

HON C Y，TESCHKE K，SHEN H，et al. Antineoplastic drug contamination in the urine of Canadian healthcare workers[J]. Int Arch Occup Environ Health，2015，88（7）：933-941.

The United States Pharmacopeial Convention （USP）.USP General chapter hazardous drugs：handling in healthcare settings [EB/OL].（2014-11-01）[2023-06-02]. https：//www.uspnf.com/es/node/2881https://www.uspnf.com/es/node/2881.

KIM O，LEE H，JUNG H，et al. Korean nurses’ adherence to safety guidelines for chemotherapy administration[J]. Eur J Oncol Nurs，2019，40：98-103.

LAWSON C C，JOHNSON C Y，NASSAN F L，et al. CE：original research：antineoplastic drug administration by pregnant and nonpregnant nurses：an exploration of the use of protective gloves and gowns[J]. Am J Nurs，2019，119（1）：28-35.

LABRÈCHE F，OUELLET C，ROBERGE B，et al. Occupational exposure to antineoplastic drugs：what about ho- spital sanitation personnel?[J]. Int Arch Occup Environ Health，2021，94（8）：1877-1888.

国家卫生健康委.静脉用药调配中心建设与管理指南（试行）：国卫办医函〔2021〕598号[EB/OL].（2021-12-10）[2023-06-02]. http：//www.gov.cn/zhengce/zhengceku/2021-12/21/content 5663666.htmhttp://www.gov.cn/zhengce/zhengceku/2021-12/21/content5663666.htm.

Occupational Safety and Health Administration （OSHA）. Controlling occupational exposure to hazardous drugs[EB/OL].（2016-08-01）[2023-06-02]. https：//compliancetrainingpartners.com/wp-content/uploads/2021/08/Hazardous-Drugs-Controlling-Occupational-Exposure.pdfhttps://compliancetrainingpartners.com/wp-content/uploads/2021/08/Hazardous-Drugs-Controlling-Occupational-Exposure.pdf.

ARNOLD S，KAUP H M. Assessing variability of antineoplastic drugs handling practices in clinical settings[J]. J Occup Environ Hyg，2019，16（12）：757-762.

NABHANI GEBARA S，BARTON S，APPLEFORD I， et al. Consensus recommendations for the safe handling of cytotoxic agents in cytotoxic academic research laboratories （CARL）[J]. J Oncol Pharm Pract，2020，26（8）：1953-1963.

CONNOR T H，DEBORD D G，PRETTY J R，et al. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers[J].J Occup Environ Med，2010，52（10）：1019-1027.

BURROUGHS G E，CONNOR T H，MCDIARMID M A，et al. NIOSH Alert：preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings[EB/OL].（2018-02-07）[2023-06-02]. https：//www.cdc.gov/niosh/docs/2004-165/https://www.cdc.gov/niosh/docs/2004-165/.

ACRAMEL A，FOUQUE J，BLONDEEL-GOMES S，et al. Application of an environmental monitoring to assess the practices and control the risk of occupational exposure to cyclophosphamide in two sites of a French comprehensive cancer center[J]. Ann Work Expo Health，2022，66（9）：1215-1223.

YASUI H. Safe handling of cancer chemotherapy drugs[J]. Gan to Kagaku Ryoho，2016，43（5）：503-508.

National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings[EB/OL].（2018-02-28）[2023-06-02]. www.cdc.gov/niosh/docs/2016-161/default.htmlwww.cdc.gov/niosh/docs/2016-161/default.html.

Pan American Health Organization.Safe handling of hazardous chemotherapy drugs in limited-resource settings[EB/OL]. [2023-06-02]. https：//goo.gl/zUoyFkhttps://goo.gl/zUoyFk.

NEUSS M N，GILMORE T R，BELDERSON K M，et al. 2016 updated American Society of Clinical Oncology/ Oncology Nursing Society chemotherapy administration safety standards，including standards for pediatric oncology[J]. J Oncol Pract，2016，12（12）：1262-1271.

NSW Goverment. Cytotoxic drugs and related waste-risk management [EB/OL].[2023-06-02]. https：//www.safework.nsw.gov.auhttps://www.safework.nsw.gov.au.

Cytotoxic drugs and related waste：a risk management guide for south Australia health services[EB/OL]. （2014-12-30） [2023-06-02]. https：//www.sahealth.sa.gov.au/wps/wcm/connect/f8aa68004b3f6cf6a340afe79043faf0/Safe+Handling+Cytotoxic+Guidelines.pdf?MOD=AJPEREShttps://www.sahealth.sa.gov.au/wps/wcm/connect/f8aa68004b3f6cf6a340afe79043faf0/Safe+Handling+Cytotoxic+Guidelines.pdf?MOD=AJPERES.

LIN Y，CHANG Y，LIN Y C，et al. Factors influencing nurses’ use of hazardous drug safe handling precautions[J]. Oncol Nurs Forum，2019，46（3）：E86-E97.

CRICKMAN R，FINNELL D.Systematic review of control measures to reduce hazardous drug exposure for health care workers[J].J Nurs Care Qual，2016，31（2）：183-190.

魏诗晴，凃敏，赖晓全，等.我国各类医疗机构部分医疗废物分类处置现状[J].中国感染控制杂志，2021，20（9）：782-787.

HILLIQUIN D，TANGUAY C，BUSSIÈRES J F. External contamination of commercial containers by antineoplastic agents：a literature review[J]. Eur J Hosp Pharm，2020，27（5）：313-314.

吴安华，任南. 医疗机构医疗废物管理技术[J]. 中国护理管理，2003，3（5）：59-62.

国务院.医疗废物管理条例[EB/OL].[2023-06-02].https：//www.gov.cn/gongbao/content/2011/content_1860802.htmhttps://www.gov.cn/gongbao/content/2011/content_1860802.htm.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Review and comment rules of national key monitoring drug prescriptions （medical orders）

Principles for the rational use of national key monitoring drugs （the second batch）

Related Author

YANG Liu

HAN Yong

SHEN Qing

ZHOU Yimeng

REN Wei

YAN Junfeng

TONG Rongsheng

BIAN Yuan

Related Institution

Dept. of Pharmacy， Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital

Sichuan Provincial Key Laboratory of Personalized Drug Therapy， the Affiliated Hospital of UESTC

Dept. of Pharmacy/Sichuan Provincial Key Laboratory of Personalized Drug Therapy， the Affiliated Hospital of University of Electronic Science and Technology of China

Personalized Drug Therapy Key Laboratory of Sichuan Provincial，Dept. of Pharmacy，Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital/ Affiliated Hospital of UESTC

四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部个体化药物治疗四川省重点实验室

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰